Characterization of tumor-infiltrating lymphocytes and their spatial distribution in triple-negative breast cancer

Table 5 Multivariate analyses of disease-free survival

Model	Variables	Category	Multivariate analysis
Model	Variables	Category	HR (95% CI)	p value
A	T stage	T1-2 vs. T3-4	2.008 (0.573–7.036)	0.276
	N stage	N0 vs. N1-3	1.129 (0.449–2.842)	0.796
	LVI	Absent vs. Present	2.784 (1.050–7.385)	0.040
	TIL	< 10% vs. ≥10%	0.546 (1.050–7.385)	0.163
B	T stage	T1-2 vs. T3-4	1.677 (0.480–5.859)	0.418
	N stage	N0 vs. N1-3	1.007 (0.395–2.563)	0.989
	LVI	Absent vs. Present	3.055 (1.160–8.041)	0.024
	CD4⁺ TIL	Low vs. High	0.307 (0.112–0.841)	0.022
C	T stage	T1-2 vs. T3-4	2.170 (0.624–7.549)	0.223
	N stage	N0 vs. N1-3	1.143 (0.456–2.869)	0.776
	LVI	Absent vs. Present	2.822 (1.086–7.331)	0.033
	CD8⁺ TIL	Low vs. High	0.312 (0.115–0.844)	0.022
D	T stage	T1-2 vs. T3-4	2.012 (0.570–7.094)	0.277
	N stage	N0 vs. N1-3	1.140 (0.441–2.952)	0.787
	LVI	Absent vs. Present	2.676 (0.985–7.275)	0.054
	CD56⁺ TIL	Low vs. High	0.441 (0.169–1.150)	0.094
E	T stage	T1-2 vs. T3-4	2.486 (0.718–8.602)	0.150
	N stage	N0 vs. N1-3	1.210 (0.483–3.029)	0.684
	LVI	Absent vs. Present	2.853 (1.098–7.413)	0.031
	CD57⁺ TIL	Low vs. High	0.462 (0.188–1.132)	0.091
F	T stage	T1-2 vs. T3-4	1.752 (0.489–6.275)	0.389
	N stage	N0 vs. N1-3	1.211 (0.486–3.021)	0.681
	LVI	Absent vs. Present	2.838 (1.085–7.423)	0.034
	GNLY⁺ TIL	Low vs. High	0.525 (0.207–1.332)	0.175
G	T stage	T1-2 vs. T3-4	2.239 (0.651–7.709)	0.201
	N stage	N0 vs. N1-3	1.173 (0.46–2.957)	0.735
	LVI	Absent vs. Present	2.829 (1.081-7.400)	0.034
	CTL-NK score	0–1 vs. 2–5	0.420 (0.181–0.978)	0.044

p values were calculated by Cox proportional hazards model using the backward stepwise selection method
HR, hazard ratio; CI, confidence interval; TIL, tumor-infiltrating lymphocyte; GNLY, granulysin; GZMB, granzyme B

ISSN: 1465-542X